Przejdź do zawartości
Merck

Semi-interpenetrating network (sIPN) co-electrospun gelatin/insulin fiber formulation for transbuccal insulin delivery.

Pharmaceutical research (2014-07-18)
Leyuan Xu, Natasha Sheybani, Shunlin Ren, Gary L Bowlin, W Andrew Yeudall, Hu Yang
ABSTRAKT

This work was aimed at developing a semi-interpenetrating network (sIPN) co-electrospun gelatin/insulin fiber scaffold (GIF) formulation for transbuccal insulin delivery. Gelatin was electrospun into fibers and converted into an sIPN following eosin Y-initiated polymerization of polyethylene glycol diacrylate (PEG-DA). The cytocompatibility, degradation rate and mechanical properties were examined in the resulting sIPNs with various ratios of PEG-DA to eosin Y to find a suitable formulation for transbuccal drug delivery. Insulin was co-electrospun with gelatin into fibers and converted into an sIPN-GIF using this suitable formulation. The in vitro release kinetics of insulin was evaluated using ELISA. The bioactivity of released insulin was analyzed in 3T3-L1 preadipocytes using Western blotting and Oil Red O staining. The transbuccal permeability of released insulin was determined using an in vitro porcine oral mucosa model. The sIPN-GF formulation of GF cross-linked by PEG-DA (1% w/v) with eosin Y (5% v/v) possessed no cytotoxic effect, a moderate degradation rate with degradation half-life of 49 min, and a significant enhancement in mechanical properties. This formulation was used to fabricate sIPN-GIF. Insulin release was extended up to 4 h by sIPN-GIF. The released insulin successfully triggered intracellular AKT phosphorylation and induced adipocyte differentiation in 3T3-L1 preadipocytes. The transbuccal permeability of released insulin was determined on the order of 10(-7) cm/s. Insulin can be fabricated into an sIPN-GIF formulation following co-electrospinning and cross-linking without losing bioactivity. It proved the potential of this new formulation for transbuccal insulin delivery.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
1-Vinyl-2-pyrrolidinone, contains sodium hydroxide as inhibitor, ≥99%
Sigma-Aldrich
Triethanolamine, ≥99.0% (GC)
Sigma-Aldrich
Triethanolamine, puriss. p.a., ≥99% (GC)
Sigma-Aldrich
Triethanolamine, reagent grade, 98%
Sigma-Aldrich
Triethanolamine, puriss., meets analytical specification of NF, ≥99% (GC)
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Triethanolamine, BioUltra, ≥99.5% (GC)
Supelco
Triethanolamine, analytical standard
Supelco
Dexamethasone, VETRANAL®, analytical standard
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
Eosin Y solution, 5 wt. % in H2O
Sigma-Aldrich
Eosin Y, 75% (HPLC)
Supelco
1,1,1,3,3,3-Hexafluoro-2-propanol, derivatization grade (GC derivatization), LiChropur, ≥99.8%
Sigma-Aldrich
1,1,1,3,3,3-Hexafluoro-2-propanol, ≥99%
Sigma-Aldrich
Eosin Y, Dye content ~99 %
Sigma-Aldrich
3-Isobutyl-1-methylxanthine, BioUltra, ≥99%
Sigma-Aldrich
3-Isobutyl-1-methylxanthine, ≥99% (HPLC), powder
Sigma-Aldrich
Eosin Y disodium salt, certified by the BSC
Sigma-Aldrich
Eosin Y disodium salt, ≥85 % by HPLC
Trolamine, European Pharmacopoeia (EP) Reference Standard
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard